Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomorphine inhalation - Vectura

Drug Profile

Apomorphine inhalation - Vectura

Alternative Names: VR 004; VR 040; VR 400

Latest Information Update: 06 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vectura
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Erectile dysfunction; Female sexual dysfunction; Parkinson's disease

Most Recent Events

  • 01 Sep 2011 Apomorphine inhalation - Vectura is still available for licensing. http://www.vectura.com
  • 31 Mar 2011 Vectura completes a phase II trial in Parkinson's disease in the UK (EudraCT2005-005120-13)
  • 11 Jun 2010 Vectura's inhaled apomorphine product is still in Phase-II trials for Parkinson's disease in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top